FUKOKU MUTUAL LIFE INSURANCE Co Has $913,000 Holdings in Boston Scientific Co. (NYSE:BSX)

FUKOKU MUTUAL LIFE INSURANCE Co raised its stake in Boston Scientific Co. (NYSE:BSX) by 5.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,225 shares of the medical equipment provider’s stock after purchasing an additional 500 shares during the quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Boston Scientific were worth $913,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. MONECO Advisors LLC grew its stake in shares of Boston Scientific by 7.6% in the 3rd quarter. MONECO Advisors LLC now owns 3,861 shares of the medical equipment provider’s stock worth $324,000 after acquiring an additional 272 shares in the last quarter. Jacobsen Capital Management grew its holdings in shares of Boston Scientific by 4.9% in the third quarter. Jacobsen Capital Management now owns 2,820 shares of the medical equipment provider’s stock valued at $236,000 after acquiring an additional 133 shares in the last quarter. Highview Capital Management LLC DE lifted its holdings in Boston Scientific by 17.2% during the third quarter. Highview Capital Management LLC DE now owns 23,068 shares of the medical equipment provider’s stock worth $1,933,000 after acquiring an additional 3,388 shares during the period. Adams Diversified Equity Fund Inc. purchased a new position in Boston Scientific in the third quarter worth $17,908,000. Finally, Golden State Equity Partners raised its stake in shares of Boston Scientific by 1.4% during the 3rd quarter. Golden State Equity Partners now owns 10,614 shares of the medical equipment provider’s stock worth $889,000 after purchasing an additional 151 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on BSX. UBS Group increased their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Royal Bank of Canada raised their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Citigroup increased their price objective on Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Truist Financial boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $107.39.

Boston Scientific Stock Performance

Shares of BSX stock opened at $101.61 on Thursday. The firm has a market capitalization of $149.96 billion, a PE ratio of 81.29, a P/E/G ratio of 2.79 and a beta of 0.80. The company has a 50 day moving average price of $98.73 and a 200-day moving average price of $89.95. Boston Scientific Co. has a 52 week low of $65.52 and a 52 week high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the sale, the executive vice president now owns 29,308 shares in the company, valued at $2,660,580.24. The trade was a 19.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daniel J. Brennan sold 67,333 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the transaction, the chief financial officer now owns 225,808 shares of the company’s stock, valued at $23,764,033.92. This represents a 22.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 144,305 shares of company stock worth $14,954,985 in the last three months. Corporate insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.